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Georgia Kourlaba1*, Nikos Maniadakis2, George Andrikopoulos3 and Panos Vardas4Abstract
Background: To undertake an economic evaluation of rivaroxaban relative to the standard of care for stroke
prevention in patients with non-valvular atrial fibrillation (AF) in Greece.
Methods: An existing Markov model designed to reflect the natural progression of AF patients through different
health states, in the course of three month cycles, was adapted to the Greek setting. The analysis was undertaken
from a payer perspective. Baseline event rates and efficacy data were obtained from the ROCKET-AF trial for
rivaroxaban and vitamin-K-antagonists (VKAs). Utility values for events were based on literature. A treatment-related
disutility of 0.05 was applied to the VKA arm. Costs assigned to each health state reflect the year 2013. An
incremental cost effectiveness ratio (ICER) was calculated where the outcome was quality-adjusted-life year (QALY)
and life-years gained. Probabilistic analysis was undertaken to deal with uncertainty. The horizon of analysis was
over patient life time and both cost and outcomes were discounted at 3.5%.
Results: Based on safety-on-treatment data, rivaroxaban was associated with a 0.22 increment in QALYs compared
to VKA. The average total lifetime cost of rivaroxaban-treated patients was €239 lower compared to VKA.
Rivaroxaban was associated with additional drug acquisition cost (€4,033) and reduced monitoring cost (-€3,929).
Therefore, rivaroxaban was a dominant alternative over VKA. Probabilistic analysis revealed that there is a 100%
probability of rivaroxaban being cost-effective versus VKA at a willingness to pay threshold of €30,000/QALY gained.
Conclusion: Rivaroxaban may represent for payers a dominant option for the prevention of thromboembolic
events in moderate to high risk AF patients in Greece.
Keywords: Cost-effectiveness, Vitamin-K-antagonists, Cost-utilityBackground
Atrial Fibrillation (AF) constitutes a significant public
health problem as it is strongly associated with increased
risk of morbidity, such as stroke, heart failure, left ven-
tricular dysfunction and thromboembolism, increased
risk of mortality and reduced quality of life (QoL) [1-3].
Stroke is the most devastating and feared complication
of AF, and in the absence of anti-thrombotic therapy the* Correspondence: kurlaba@gmail.com
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stated.annual risk of stroke in patients with non-valvular AF
increases from about 5% in patients less than 65 years of
age to about 8% in patients 75 years of age or older [1].
Along with mortality and morbidity, AF imposes a great
economic burden which stems from the excess health
care resources utilization related to the management of
the disease as well as its complications [4-7].
Taking into account the aforementioned, the need for
effective and efficient management of AF patients is evi-
dent. The care of AF patients should be focused on redu-
cing the symptoms and preventing severe AF-related
complications. The guidelines issued by the European
Society of Cardiology and American Heart Association as
well as local guidelines issued recently by the National
Medicines Agency, advocate that antithrombotic therapy,al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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combination of OAC with anti-platelets, represent good
options in the effective prevention of complications asso-
ciated with AF [8-10]. Moreover, guidelines suggest that
the management of AF patients should vary according to
their risk status for stroke, defined by the CHADS2 (Car-
diac failure, Hypertension, Age, Diabetes, Stroke2) Index
[11]. Specifically, patients with medium to high risk of
stroke should be receiving OAC, such as vitamin K antag-
onists (VKA) including warfarin and acenocoumarol. A
recent meta-analysis revealed that VKA-treated patients
experience significantly lower risk for stoke compared to
those receiving placebo or remain untreated [12]. How-
ever, VKA anti-coagulation has a narrow therapeutic win-
dow and requires regular blood monitoring to ensure that
patients are within optimal therapeutic ranges, defined as
International Normalised Ratios (INRs) between 2.0 and
3.0. In addition, OACs have a number of known drug and
food interactions, and thus maintaining patients in the
narrow therapeutic window of INR 2-3 is difficult. There-
fore, there is a need for effective and safe OACs that are
simpler to administer.
Rivaroxaban (Xarelto®), an oral direct factor Xa inhibitor,
represents a new OAC option for use in this group of pa-
tients [13]. The “Rivaroxaban Once Daily Direct Factor Xa
Inhibition Compared with Vitamin K Antagonism for Pre-
vention of Stroke and Embolism Trial in Atrial Fibrilla-
tion” (ROCKET AF) was designed to determine whether
rivaroxaban (at a daily dose of 20 mg) is non-inferior to
dose-adjusted VKA for the primary end point of stroke
(ischaemic and haemorrhagic stroke) or systemic em-
bolism (SE) [14,15]. In the safety on-treatment analysis
(SOT), rivaroxaban demonstrated a 21% relative risk re-
duction for stroke and SE compared with warfarin (hazard
ratio 0.79, 95% confidence interval [CI] 0.65–0.95, p = 0.02
for superiority test) [15]. Thus, it represents an effective
alternative for stroke prevention, but it also may impose a
considerable cost to the health care system and payers.
The recent climate of the major financial crisis has re-
sulted in strong health care budgetary constraints and
more than ever before emerges the need to increase the
efficiency in health care delivery and the cost-effectiveness
of interventions. In this light, the aim of the present study
was to conduct an economic evaluation comparing rivar-
oxaban (Xarelto®) with the standard therapy (i.e. VKAs)
for stroke prevention in patients with AF in the Greek
healthcare setting.
Methods
In the present study, an existing Markov model evaluat-
ing the lifetime cost-effectiveness of rivaroxaban relative
to selected antithrombotic alternatives for stroke preven-
tion in AF patients was adapted to the Greek health care
setting. The analysis was conducted from the Greekthird-party payer perspective. Costs and outcomes that
occur beyond one year were discounted at a 3.5% annual
rate which is the standard practice in these studies in
Greece [16].
Model structure
The model was designed to reflect the natural progression
of AF patients through different health states, during the
course of three month cycles and its aim was to suffi-
ciently capture the frequency of major events, up to death.
The model structure is depicted in simplified form in
Figure 1. In particular, patients enter the model with stable
uncomplicated AF and are being treated with rivaroxaban
or VKAs. Then, in each subsequent three month cycle
during their life span, patients can either remain without
any event or experience one of the following complica-
tions: major and minor ischemic stroke (IS), systemic em-
bolism (SE), myocardial infarction (MI), major and minor
extracranial (EC) bleeding, intracranial (IC) bleeding or
death from AF-related cause or other causes. The major
events may be classified as transient events or events with
permanent after-effects. The IC bleed event may result in
discontinuation of the current OAC treatment depend-
ing on the stroke risk of the population. Patients cannot
experience two acute complications in the same cycle.
Patients can also switch or discontinue treatment per-
manently for reasons not related to a clinical event.
Patient population
The hypothetical cohort of 1000 patients entering the
Markov model is assumed to be representative of the
Greek patients with non-valvular AF and with at least
one risk factor for stroke. Based on data obtained from
an ongoing study entitled “Current Clinical Practice in
the Management of Atrial Fibrillation in Greece: The
MANAGE-AF study” the mean age of AF patients in
Greece is 75 years (“data on file”). Therefore, 75 years
was used as the starting age in the model. At this point,
it should be mentioned that the UK’s National Institute
of Health and Clinical Excellence (NICE) concluded that
there is no reason to believe that the efficacy/safety ex-
tracted from ROCKET-AF would be different in patients
at low risk of stroke based on the pharmacokinetics [17].
Sub-populations such as those at high risk of stroke,
those with prior stroke, poorly controlled VKA-patients
as well as VKA-naïve patients were considered in sensi-
tivity analyses.
Comparators
The most widely used antithrombotic alternatives in the
common clinical practice for stroke prevention in AF pa-
tients were considered as comparators of rivaroxaban in
the present analysis. In particular, adjusted-dose VKA (i.e.
acenocoumarol, up to 2.5 mg per day, that is widely used
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Figure 1 Model structure.
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therapeutic INR of 2.0 to 3.0, represents the standard of
care. In the case of a discontinuation, it is assumed that
patients who received either rivaroxaban or VKA are
switched to aspirin monotherapy. An alternative scenario
where both rivaroxaban and VKA-treated patients are
switched to no treatment was also considered in sensitivity
analysis.
Model inputs
In each different health state a treatment cost is attached,
in order to estimate the total and the mean cost of ther-
apy, based on the progression of patients from the original
cohort through different health states. In a similar manner,
each health state is also associated with a utility weight,
which reflects quality of life in that particular state, and is
used in order to estimate total and mean lived years with
and without quality of life adjustment.
Efficacy and safety data
In a Markov model, patients move from one health state
to another with a certain probability called “transition
probability”. Transition probabilities for all stages of a
treatment cycle are usually obtained from available clinical
trials, observational studies and meta-analyses. In the
current study, transition probabilities were calculated
based on event rates and relative treatment effects (RRs)
obtained from the phase III ROCKET AF trial [15]. The
quarterly VKA rates for IS, SE, bleeding events and MI
obtained from the SOT analysis of the ROCKET AF wereused as baseline rates [15]. In particular, the quarterly rates
were calculated based on the corresponding annual rates
reported in the ROCKET AF trial by the following for-
mula: Quarterly rate = 1 − (1 − annual rate) ^ 1/4 (Table 1).
Relative treatment effects (RRs) describing the efficacy
of rivaroxaban versus VKA for IS, SE, bleeding events
and MI were extracted from the ROCKET AF [15,18]. In
the base case analysis, the RRs for IS, MI, SE and bleed
derived from SOT analysis of the ROCKET AF trial data
were considered, to be comparable with previous relative
studies [22,23], while the RRs for IS, MI and SE obtained
from intention-to-treat (ITT) analysis were used in sensi-
tivity analysis. Because bleed events are safety endpoints,
it was not appropriate to also consider RRs from the ITT
population (Table 1). At this point, it should be noted that
for the current analysis where the discontinuation is being
modelled (i.e. event rates on and off-treatment), the most
appropriate data to use depend on the treatment assump-
tions to avoid the double-counting of the impact of
discontinuation on events. More specifically, as long as
patients are on treatment the SOT data are most relevant,
once off-treatment data related to the selected second line
treatment must be applied (e.g. aspirin from an additional
external source).
After major IS, major EC bleeding events, MI and IC
bleeding events, patients may die with a probability equal
to the case-fatality rate extracted from the SOT analysis of
ROCKET AF trial data [15]. This case fatality rate was
based on the average of case fatality rates in both arms of
the ROCKET AF trial, thus making the assumption that






VKA 0.40% ROCKET AF [15] §
Myocardial infarction
VKA 0.28% ROCKET AF [15]§
Systemic embolism
VKA 0.05% ROCKET AF [15]§
Intracranial bleeding
VKA 0.19% ROCKET AF [15]§
Minor extracranial bleeding
VKA 2.97% ROCKET AF [15]§
Major extracranial bleeding
VKA 0.69% ROCKET AF [15]§
RR (95% CI) Sources
Ischemic stroke
Rivaroxaban vs. VKA (SOT) 0.94 (0.75 – 1.17) ROCKET AF [18]
Rivaroxaban vs. VKA (ITT) 0.99 (0.82 – 1.20) ROCKET AF [15]
Myocardial infarction
Rivaroxaban vs. VKA (SOT) 0.81 (0.63 – 1.06) ROCKET AF [15]
Rivaroxaban vs. VKA (ITT) 0.91 (0.72 – 1.16) ROCKET AF [15]
Systemic embolism
Rivaroxaban vs. VKA (SOT) 0.23 (0.09 – 0.61) ROCKET AF [18]
Rivaroxaban vs. VKA (ITT) 0.74 (0.42 – 1.32) ROCKET AF [15]
Intracranial bleeding
Rivaroxaban vs. VKA 0.67 (0.47 – 0.93) ROCKET AF [15]§
Major extracranial bleeding
Rivaroxaban vs. VKA 1.14 (0.98 – 1.33) ROCKET AF [18]§
Minor extracranial bleeding
Rivaroxaban vs. VKA 1.04 (0.96 – 1.13) ROCKET AF [15]§
Mortality rates¶ Sources
Stroke related
Case fatality of major stroke 12.6% ROCKET AF [15]
Case fatality of minor stroke 0.00% Assumption
Post-major stroke mortality
rate
2.60% Marini et al.
2005 [19]
Post-minor mortality rate 0.00% Assumption
Bleeding-related
Case-fatality of major bleed 1.60% ROCKET AF [15]
Case-fatality of minor bleed 0.00% Assumption
Case-fatality of intracranial
bleed
38.80% ROCKET AF [15]
Post- major bleed mortality
rate
0.00% Assumption
Post- minor bleed mortality
rate
0.00% Assumption
Table 1 Event rates and relative risks of clinical events












9.69% ROCKET AF [15]
Post myocardial infarction
mortality rate
2.68% Hoit et al.
1986 [21]
SOT safety on treatment, ITT Intention-to-Treat, VKA vitamin-K-antagonist.
¶based on the sum of case fatality rates in both arms of the ROCKET trial.
§Data derived from safety on treatment analysis of ROCKET trial.
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the patient is receiving [15]. Minor IS and minor bleeding
events with no lasting sequelae as well as the SE were as-
sumed to have no associated case-fatality. For patients
who have experienced a major IS and a MI, there is evi-
dence for an impact on life expectancy, which means an
increased mortality rate even after recovery from the acute
episode. Since post-recovery mortality data is not available
for the ROCKET AF trial, these mortality rates were esti-
mated based on literature [19,21]. Moreover, since no lit-
erature on post-IC bleed mortality rates was found, the
increase in subsequent mortality rates was assumed to be
equal to that following a major IS [19]. Finally, patients re-
covering from a major bleed are expected to fully recover
over the duration of three months, and thus no increase
in subsequent mortality rate has been assumed (Table 1).Discontinuation and switching
Persistence indicates whether or not patients continue
or discontinue their current treatment. As an initial step
towards adjusting the efficacy which is associated with a
clinical trial, permanent discontinuation rates in an ob-
servational setting can be used to describe the propor-
tion of patients who cease to receive treatment entirely.
Although limited data for the real-life discontinuation
rate is available for rivaroxaban, the model currently uses
discontinuation rates from the ROCKET AF trial [15] as
the real-life available data indicates that the discontinuation
rate for the first 3-month follow up period is extremely
close to that obtained from ROCKET data (9.1% and 8.9%,
respectively). In this context, the discontinuation rate was
set at 8.9% and 8.0% for rivaroxaban and VKA, respectively
as concerns the initial cycle and at 4.39% and 4.46%, re-
spectively in subsequent cycles, based on data from the
ROCKET AF trial. Discontinuation probabilities were cal-
culated based on the proportion of patients persisting on
Table 2 Cost inputs used in the base case analysis
Cost inputs Costs (€) Sources
Drug acquisition cost (per day)
Rivaroxaban 2.16 Drug price bulletin [36]
VKA (Acenocoumarol) 0.05 Positive Drug List [37]
Monitoring cost
VKA monitoring visit (1st visit) 32 Government Gazzette
VKA monitoring visit (subsequent
visits)
22 Government Gazzette
Other therapies monitoring visit 10 Government Gazzette
Acute treatment event cost
Minor ischemic stroke 900 DRGs (N30X)
Moderate ischemic stroke 1625 DRGs (N30Mβ)
Severe ischemic stroke 2475 DRGs (Ν30Μα)
Systemic embolism 1567 DRGs (K45Mβ, Κ45Μα)§
Intracranial haemorrhage 2,475 DRGs (Ν30Μα)
Minor extracranial haemorrhage 257 DRGs (Ξ21Χ)
Major extracranial haemorrhage 654 DRGs (Π41Μ, Π41Χ)§
Acute myocardial infarction 1,783 DRGs (K10M, K10X, K31M,
K31X, K40M, K40X)§
Follow up cost per three month cycle
Major stroke 1,093 THESIS study [35]
Intracranial haemorrhage 1,093 Assumption
Myocardial infarction 1,296 THESIS study [35]
All costs reflect the year 2013.
§weighted mean of related DRGs has been calculated taking into account the
proportion of patients belongs to each DRG code, based on expert’s opinion.
VKA vitamin-K-antagonist, DRG Diagnostic Related Group.
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lowing formulae:
Discontinuation at 3 months ¼ 1−x
Subsequentdiscontinuation ¼ 1− 1− y−xð Þ 1^=3ð Þ:
Utility values
Utility values describe the health-related QoL associated
with different health states on a scale of zero to one,
where zero is equivalent to death and one represents
best imaginable health. Due to lack of local utility values
for patients with AF on or off anti-thrombotic therapy,
the values proposed by published studies in the literature
were considered in the present analysis [24-30]. These
values have been obtained by measuring QoL of these
patients with the EQ-5D instrument. In particular, a util-
ity value of 0.779 was assigned to the baseline untreated
state of an AF patient [31]. The same value was assigned
for those receiving rivaroxaban as it was assumed that
there is no disutility associated with this therapy. On the
other hand, a treatment-related disutility of 0.05 was ap-
plied to VKA. This was obtained from a study evaluating
how patients with AF (attending GP- and hospital-led
clinics) value different health outcomes [25]. An alterna-
tive scenario with no VKA-related disutility in the model
was considered in the sensitivity analysis. The utility
values of 0.189, 0.641 and 0.680 were assigned to the three
health states describing the acute episodes of major and
minor IS as well as MI [25,32], while the values of 0.72,
0.48, and 0.69 were considered for the post minor and
post major IS and post MI [26,33]. As concerns bleeding
events, the utility values of 0.776 and 0.598 were assigned
to minor and major bleeds [24], while a value of 0.60 was
used for IC bleed events and 0.74 to reflect QoL of pa-
tients in the post IC bleed event period [27,28]. Finally, a
value of 0.66 was used in association to the systemic SE
state [24].
Estimation of costs
The perspective of the economic evaluation was that of the
public third-party-payer and as such only health care costs
reimbursed by the payer were considered in the analysis
and any other cost, such as the cost related to the central
Government budget to cover personnel salaries or patient
co-payments, were not considered. In particular, drug ac-
quisition costs, monitoring costs, event treatment-related
costs (acute and follow-up costs), patient reimbursed trans-
portation costs were the main ones considered in the
model. All costs reflect the year 2013.
The reimbursement costs to payers associated with
acute treatment of IS, SE, MI, IC and EC bleeding events
were obtained from the corresponding Diagnostic Re-
lated Group (DRG) tariffs, which were issued recently bythe Greek Ministry of Health [34]. A major IS, IC bleed-
ing and MI also incurred a cost associated with follow-
on care for the rest of patients’ life. The 3-month cost of
care for IS and MI was extracted from a published study
which detailed different components of the follow-up
cost of patients with stroke and MI in Greece (Table 2)
[35]. The follow-up cost for IC bleeding was assumed to
be identical to corresponding cost for a major IS. With
regards to major EC bleedings and SE, it was assumed
that there were no subsequent costs after 3 months.
The cost of medications was estimated on the basis of
the defined daily dose and corresponding cost. In the
base case analysis, the drug daily cost was calculated on
grounds of the social security reimbursement price, de-
fined by the internal reference price system attached to
the latest published positive drug list (May 2013) [37]. In
particular, when the drug retail price was higher than
the corresponding reimbursement one, the payer cost was
calculated based on the reference price minus the patient
co-payment (25%), plus 50% of the difference between ref-
erence price and retail prices. On the other hand, when
the retail price was lower than the reference price, the
payer cost was obtained from the reference price minus
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reimbursement price (i.e. in case of rivaroxaban), the avail-
able retail price published in the latest drug price bulletin
issued by the Greek Ministry of Health was used (August
2013) [36]. Moreover, there is a rebate of 9% imposed
upon manufacturers to get into the positive drug list and
then there is one more based on volume which can be
up to 8% depending on quarterly sales (law 4052/2012,
Government Gazzette). At this point, it should be noted
that a conservative 5% volume-related rebate was con-
sidered on top of the 9% rebate to enter the positive list.
The monitoring cost is associated with physician mon-
itoring visits and utilization of INR tests to evaluate the
effectiveness of therapy. Rivaroxaban is fixed-dose oral
therapy that does not require any blood monitoring.
Therefore, the monitoring cost related to this therapy is
equal only to the visit cost, which is assumed to be two
per year, based on expert opinion. On the other hand,
VKAs require regular INR monitoring and dose-titration
over the duration of therapy. Especially, when patients
are initiated on VKA for the first time, or after a period
of therapy interruption, it is recommended that they see
a physician regularly and frequently in order to adjust
the dose of VKA until they have achieved stabilisation in
their INR. Based on local expert opinion, one visit per
week (including an INR test) is required during the first
month and then once monthly. The per visit cost of a
monitoring visit in Greece as well as the cost of INR test
were obtained from the Government Gazzette (Table 2).
In addition, the cost of using patient transport services
to attend the VKA monitoring clinics was incorporated.
Some proportion of patients makes use of the third-
party payer-sponsored patient transport service (PTS)
for their transportation. A conservative 50% of patients
were assumed to use this service, and a mean transpor-
tation cost of €70 per visit was considered based on a
previous analysis regarding average distance and travel-
ling cost per patient and the cost to the sickness funds
[38]. A zero transportation cost was also considered in
the sensitivity analysis.
Data analysis
The aforementioned approach and data were used to
get mean estimates of life time costs, LYs and QALYs
for each comparator. When new options like rivaroxa-
ban are more effective (i.e. higher QALY) and less costly
than comparators, they are considered as “dominant”
treatments. In cases where new options are less effective
and more costly they are considered as “dominated” by
the alternatives. In cases where they are associated with
higher QALY and higher cost they are considered as
cost-effective only when the ICER is lower than a spe-
cific predetermined willingness-to-pay (WTP) threshold
(i.e. €40,000/QALY which is a commonly used standardor €60,000/QALY that corresponds to three times per
capita GDP in Greece, as recommended by the World
Health Organisation) [39-41]. There is no official WTP
threshold for Greece and in published studies the above
thresholds are often quoted. However, in the context of
the economic crisis a much lower WTP threshold (i.e.
€30,000/QALY) was considered.
The majority of input data used in the current model
are subjected to variation. Therefore, a probabilistic sensi-
tivity analysis (PSA) was conducted to test second-order
uncertainty in the model. Hence, baseline risks were as-
sumed to have beta distributions, while relative risks were
assumed to be log-normally distributed. Event costs and
utilities were assumed to have gamma and beta distribu-
tions, respectively. Simulation modeling was used to run
1000 iterations of the model each time varying all model
parameters. The results of PSA are presented as cost-
effectiveness acceptability curves (CEAC), which indicate
the likelihood of the incremental cost per QALY to fall
below specified WTP thresholds.
One way sensitivity analysis was also undertaken to
test the robustness of the results, by varying individual pa-
rameters between low and high values, within plausible
ranges, in order to ascertain the key drivers of cost-
effectiveness. For parameters such as those reflecting clin-
ical efficacy, where values were based on robust studies or
reviews, the reported 95% CI were used. For parameters
for which there are uncertainties surrounding the source
data, ranges reported in the literature were used. Due to
the large number of input parameters included in the
model, only parameters that altered the ICER by more
than €1000 were reported. All statistical calculations were
performed using Microsoft Excel 2003.
Results
Base case analyses
The results of the base case cost-effectiveness analysis
are presented in Table 3. Based on SOT data from the
ROCKET AF trial, the analysis predicted a discounted
QALY of 6.50 and 6.28 in rivaroxaban- and VKA-treated
patients. The total lifetime cost was lower in the rivarox-
aban arm (€7,868) compared to the VKA arm (€8,107),
resulting in a cost saving of €239. Rivaroxaban was asso-
ciated with additional drug acquisition cost (€4,033),
however this was totally offset by reduced monitoring
(-€3,929) and event management (-€341) costs. There-
fore, rivaroxaban seems to be a dominant alternative
over VKA, as the former is related with lower cost and
greater health benefit.
Sensitivity analyses
Sensitivity analysis showed that rivaroxaban was a dom-
inant alternative over VKA when data derived from ITT
analysis of ROCKET AF trial was considered in the
Table 3 Cost-effectiveness results of base case analysis
(SOT analysis of ROCKET AF trial data)
Rivaroxaban VKA
Costs
Total costs (€) 7,868 8,107
Drug acquisition cost (€) 4,156 126
Drug monitoring costs (€) 52 3,981







ICER per QALY gained (€) NA Riv. Dom
ICER per LY gained (€) NA Riv. Dom
It is assumed that patients receiving either rivaroxaban or acenocoumarol are
switched to aspirin monotherapy.
SOT safety on treatment, QALYs quality-adjusted-life-years, LYs Life-Years, NA
not applicable, Riv. Dom Rivaroxaban is dominant, ICER incremental cost
effectiveness ratio, VKA vitamin-K-antagonist.
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treated with rivaroxaban and VKA were assumed to be
switched to no treatment, rivaroxaban remained a domin-
ant and a cost-effective option over VKA when SOT and
ITT data were considered in the model, respectively
(Table 4). Additionally, when excluding the VKA-related
disutility, the analysis revealed that rivaroxaban remainedTable 4 Cost-Effectiveness results for sensitivity analyses
Based on ITT data of ROCKET AF trial (switch to aspirin for
rivaroxaban and VKA-treated patients)
Rivaroxaban VKA
Total costs (€) 7,927 8,020
QALYs 6.49 6.29
ICER/QALY Gained (€) NA Riv. Dom
Based on SOT data of ROCKET AF trial
(switch to no treatment for all patients)
Total costs (€) 9,952 10,029
QALYs 6.24 6.04
ICER/QALY Gained (€) NA Riv. Dom.
Based on ITT data of ROCKET AF trial
(switch to no treatment for all patients)
Total costs (€) 9,597 9,554
QALYs 6.29 6.10
ICER/QALY Gained (€) NA 233
SOT safety on treatment, ITT intention to treat, QALY quality-adjusted-life-year,
NA not applicable, VKA vitamin-K-antagonist, Riv. Dom Rivaroxaban
is dominant.a dominant option versus VKA either in case of the SOT
or the case of the ITT approach.
The analysis conducted in specific sub-populations
showed that rivaroxaban remained a dominant alterna-
tive over VKA in patients at high risk of stroke, those
with prior stroke, and those being VKA-naïve.
Additionally, as mentioned earlier, rebates are applied
to drugs which are reimbursed and are included in the
positive drug list. When the rebate of 9% (entry rebated)
or 14% (cumulative rebate based on the entry one and
additional 5% based on sales) was incorporated into the
calculation of daily drug cost, rivaroxaban was found to
be much more cost saving alternative relative to VKA
(-€468 and -€650 for 9% and 14% respectively).
Extensive one-way sensitivity analyses were carried out
in order to identify the key drivers of cost-effectiveness.
With regards to the comparison between rivaroxaban and
VKA, the key drivers of cost-effectiveness based on cost/
QALY gained were the VKA related monitoring visits dur-
ing maintenance, the discontinuation and subsequent dis-
continuation rate with rivaroxaban and acenocoumarol,
the VKA-related utility decrement, rivaroxaban effective-
ness, the RR for rivaroxaban versus VKA for stroke and
MI, VKA monitoring costs at intitiation of therapy and
follow up and the transportation cost (Table 5).
Probabilistic sensitivity analysis
The probabilistic sensitivity analysis showed that there is
an almost 58% probability of rivaroxaban dominanting
VKA. Moreover, the likelihood of rivaroxaban being cost-
effective at a WTP threshold of €30,000/QALY was found
to be 100% in relation to acenocoumarol (Figure 2).
Discussion
In the present study, an economic evaluation was under-
taken to compare, from a payer perspective, rivaroxaban
relative to acenocoumarol for the prevention of stroke in
patients with AF in Greece. For this purpose, an existing
Markov model was adapted with local data. The input
data of the model was extracted from the ROCKET AF
trial, other published studies, experts opinion and local
government sources.
The analysis showed that rivaroxaban was a less ex-
pensive and more effective therapy over acenocoumarol.
These results held true in extensive sensitivity and prob-
abilistic analyses. Our findings are in line with those
obtained from a recent economic evaluation conducted
from a UK NHS perspective, based on the model used
in the present analysis. The ICER of rivaroxaban versus
warfarin ranged between £2,870 per QALY gained,
including warfarin-related disutility and £29,500 per
QALY gained, excluding warfarin-related disutility [17].
Moreover, another economic evaluation of rivaroxaban
compared to dose-adjusted warfarin for the prevention
Table 5 One-way sensitivity analysis for ICER of rivaroxaban vs. VKA (acenocoumarol)
Base case
value




Acenocoumarol monitoring maintenance visits 3.00 1.00 5.00 €8,635 Riv. Dom.
Subsequent discontinuation rate riva 0.04 0.00 0.09 €7,630 Riv. Dom.
Utility decrement: stable on acenocoumarol therapy 0.95 0.92 1.00 Riv. Dom. Riv. Dom.
Discontinuation rate riva 0.09 0.00 0.54 €390 Riv. Dom.
Subsequent discontinuation rate acenocoumarol 0.04 0.00 0.06 Riv. Dom. €942
Discontinuation rate acenocoumarol 0.08 0.00 0.31 Riv. Dom. €3311
Myocardial infarction RR for rivaroxaban 0.81 0.63 1.06 Riv. Dom. Riv. Dom.
Rivaroxaban effectiveness 1.00 0.75 1.25 Riv. Dom. Riv. Dom.
Stroke RR for riva 0.94 0.75 1.17 Riv. Dom. Riv. Dom.
Acenocoumarol monitoring cost – follow 22.00 17.69 26.31 €228 Riv. Dom.
Acenocoumarol monitoring cost-initiation 32 25.73 38.27 Riv. Dom. Riv. Dom.
Transport need (% of patients) 50% 0% 100% €10,388 Riv. Dom.
Other therapy monitoring visits 0.25 0 1 Riv. Dom. Riv. Dom.
VKA vitamin-K-antagonist, Riv. Dom Rivaroxaban is dominant, ICER incremental cost effectiveness ratio, QALY quality-adjusted-life-year, RR Relative Risk.
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and a lifetime horizon has been published [23]. This study
showed that treatment with rivaroxaban is related to an
additional cost of $27,498 per QALY gained over war-
farin, indicating that rivaroxaban may be a cost-effective
alternative for stroke prevention in AF. Finally, a re-
cently published cost-effectiveness study from a Belgian
healthcare payer perspective, showed that the use of riv-
aroxaban resulted in an incremental cost-effectiveness
ratio of €8,809/QALY and 7,493/LY gained [22].
When new treatments are approved for use in health
care systems, information is often limited and thus models
like the one described here present the only option to
evaluate their economic and health outcome impact.
Models are also necessary because trials are too simple
and short to capture reality in the long run. The analysis
was based on an adaptation of an international model, fol-





















Willingness to pay threshold
Figure 2 Probability of rivaroxaban being cost effective at
alternative willingness to pay thresholds: Acceptability Cost
Effectiveness Curve.literature. However, it still suffers from several limitations
and it should be viewed in that light. It does not represent
real world evidence of new oral anti-coagulants, but in-
stead it is based on the synthesis of data reported in a
RCT and in the literature that introduce uncertainty in the
results. Although the methodology adopted followed the
standard recommendations as well as conducting various
sensitivity analyses to deal with uncertainty, it cannot
substitute for real-life direct comparisons amongst the al-
ternative treatments. Hence, post-launch observational
studies are needed to verify the conclusions obtained from
analyses such as the present one. A more complete ana-
lysis of real-world efficacy and real-world prescribing be-
havior as well as a broader (societal) analysis may be
worthwhile. True health care and patient direct and indir-
ect cost are higher than those used here, and therefore the
cost-effectiveness of the new therapy may be more
favourable from a societal perspective. Moreover, in the
present analysis it was assumed that the clinical outcomes
obtained from the ROCKET AF trial were applicable to
the Greek health care setting. The use of this data may be
questionable, however given the lack of local related data,
this choice was the only source of relevant clinical data;
one may argue that pivotal trials are almost universally
used to build models for pricing and reimbursement deci-
sions. In addition, in the present study, it was assumed
that the efficacy and safety of acenocumarol was identical
to warfarin in ROCKET AF study and they differ only in
terms of their price. Based on a literature search and ex-
pert advice, acenocoumarol and warfarin do not appear to
have any statistically significant differences in terms of
total number of patients within the therapeutic range and
in terms of their efficacy and use in clinical practice
[42-45]. It should be noted that the results have to be
Kourlaba et al. Cost Effectiveness and Resource Allocation 2014, 12:5 Page 9 of 10
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the present time resource and drug prices. If any of the
underlying parameters change, so may the results and the
conclusions of the analysis.
Conclusion
In conclusion, the present economic analysis suggests that
rivaroxaban for AF patients is associated with a greater
health benefit and a lower lifetime cost relative to aceno-
coumarol. Therefore, rivaroxaban may constitute a domin-
ant alternative for prevention of thromboembolic events in
AF patients, in Greece and as such policy makers should
add in rivaroxaban in the reimbursement list to ensure pa-
tients access to this therapy.
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